Bellevue Life Sciences Acquisition Corp.
Bellevue Life Sciences Acquisition Corp. (BLAC) Revenue
Annual & quarterly revenue history · segment & region breakdown
BLAC · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBellevue Life Sciences Acquisition Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2020 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Bellevue Life Sciences Acquisition Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Bellevue Life Sciences Acquisition Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Bellevue Life Sciences Acquisition Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BLAC revenue · 4 questionsBLAC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Bellevue Life Sciences Acquisition Corp. SEC filings · GAAP · Bellevue Life Sciences Acquisition Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026